Aprogen, Inc Logo

Aprogen, Inc

Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.

007460 | KO

Overview

Corporate Details

ISIN(s):
KR7007460009
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 둔촌대로 545 경기도 성남시 중원구 둔촌대로545, 비1층 (상대원동, 한라시그마밸리), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aprogen, Inc. is a biopharmaceutical company specializing in the development and manufacturing of biologics. Leveraging proprietary technologies in antibody and recombinant protein engineering, the company creates both novel drugs and biosimilars. Its product pipeline focuses on addressing various medical needs, including treatments for degenerative arthritis and triple-negative breast cancer. Aprogen develops its own portfolio of biologics alongside biosimilar products, aiming to make advanced medicines more accessible in the global pharmaceutical market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 151.1 KB
2025-09-17 00:00
Regulatory News Service
투자판단관련주요경영사항
Korean 15.5 KB
2025-09-03 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)(자회사의 주요경영사항) (제3자배정)
Korean 31.1 KB
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 157.0 KB
2025-08-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 149.8 KB
2025-08-19 00:00
Regulatory News Service
투자판단관련주요경영사항 (독점실시권 라이선스 계약(면역항암제 기술도입 계약))
Korean 10.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 7.7 MB
2025-07-31 00:00
Regulatory News Service
단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Korean 10.4 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 155.6 KB
2025-06-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 148.5 KB
2025-06-27 00:00
Capital/Financing Update
[기재정정]주권관련사채권의처분결정(종속회사의주요경영사항)
Korean 23.5 KB
2025-06-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.3 KB
2025-06-09 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-06-02 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-05-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.4 KB

Automate Your Workflow. Get a real-time feed of all Aprogen, Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aprogen, Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aprogen, Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.